Cargando…
The Discovery of LOX-1, its Ligands and Clinical Significance
LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle ce...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204104/ https://www.ncbi.nlm.nih.gov/pubmed/21805404 http://dx.doi.org/10.1007/s10557-011-6324-6 |
_version_ | 1782215179828723712 |
---|---|
author | Yoshimoto, Ryo Fujita, Yoshiko Kakino, Akemi Iwamoto, Shin Takaya, Tomohide Sawamura, Tatsuya |
author_facet | Yoshimoto, Ryo Fujita, Yoshiko Kakino, Akemi Iwamoto, Shin Takaya, Tomohide Sawamura, Tatsuya |
author_sort | Yoshimoto, Ryo |
collection | PubMed |
description | LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not only mediates endothelial dysfunction but contributes to atherosclerotic plaque formation, thrombogenesis, leukocyte infiltration and myocardial infarction, which determine mortality and morbidity from atherosclerosis. Moreover, our recent epidemiological study has highlighted the involvement of LOX-1 in human cardiovascular diseases. Further understandings of LOX-1 and its ligands as well as its versatile functions will direct us to ways to find novel diagnostic and therapeutic approaches to cardiovascular disease. |
format | Online Article Text |
id | pubmed-3204104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-32041042011-11-10 The Discovery of LOX-1, its Ligands and Clinical Significance Yoshimoto, Ryo Fujita, Yoshiko Kakino, Akemi Iwamoto, Shin Takaya, Tomohide Sawamura, Tatsuya Cardiovasc Drugs Ther Article LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not only mediates endothelial dysfunction but contributes to atherosclerotic plaque formation, thrombogenesis, leukocyte infiltration and myocardial infarction, which determine mortality and morbidity from atherosclerosis. Moreover, our recent epidemiological study has highlighted the involvement of LOX-1 in human cardiovascular diseases. Further understandings of LOX-1 and its ligands as well as its versatile functions will direct us to ways to find novel diagnostic and therapeutic approaches to cardiovascular disease. Springer US 2011-08-02 2011 /pmc/articles/PMC3204104/ /pubmed/21805404 http://dx.doi.org/10.1007/s10557-011-6324-6 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Yoshimoto, Ryo Fujita, Yoshiko Kakino, Akemi Iwamoto, Shin Takaya, Tomohide Sawamura, Tatsuya The Discovery of LOX-1, its Ligands and Clinical Significance |
title | The Discovery of LOX-1, its Ligands and Clinical Significance |
title_full | The Discovery of LOX-1, its Ligands and Clinical Significance |
title_fullStr | The Discovery of LOX-1, its Ligands and Clinical Significance |
title_full_unstemmed | The Discovery of LOX-1, its Ligands and Clinical Significance |
title_short | The Discovery of LOX-1, its Ligands and Clinical Significance |
title_sort | discovery of lox-1, its ligands and clinical significance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204104/ https://www.ncbi.nlm.nih.gov/pubmed/21805404 http://dx.doi.org/10.1007/s10557-011-6324-6 |
work_keys_str_mv | AT yoshimotoryo thediscoveryoflox1itsligandsandclinicalsignificance AT fujitayoshiko thediscoveryoflox1itsligandsandclinicalsignificance AT kakinoakemi thediscoveryoflox1itsligandsandclinicalsignificance AT iwamotoshin thediscoveryoflox1itsligandsandclinicalsignificance AT takayatomohide thediscoveryoflox1itsligandsandclinicalsignificance AT sawamuratatsuya thediscoveryoflox1itsligandsandclinicalsignificance AT yoshimotoryo discoveryoflox1itsligandsandclinicalsignificance AT fujitayoshiko discoveryoflox1itsligandsandclinicalsignificance AT kakinoakemi discoveryoflox1itsligandsandclinicalsignificance AT iwamotoshin discoveryoflox1itsligandsandclinicalsignificance AT takayatomohide discoveryoflox1itsligandsandclinicalsignificance AT sawamuratatsuya discoveryoflox1itsligandsandclinicalsignificance |